Severe LVAD-related infections requiring surgical treatment: Incidence, predictors, effect on survival, and impact of device selection

Randall Z. Olmsted, Andre Critsinelis, Chitaru Kurihara, Masashi Kawabori, Tadahisa Sugiura, Andrew B. Civitello, Jeffrey A. Morgan

Research output: Contribution to journalArticle

Abstract

Background: Left ventricular assist devices (LVADs) are being used more frequently for treating refractory, advanced heart failure. However, infection remains a frequent complication. In this study, we analyzed the incidence of severe infections in LVAD recipients to determine its impact on survival. Methods: From May 2009 through March 2016, 437 patients with advanced heart failure underwent implantation of a continuous-flow LVAD (n = 314, HeartMate II LVAD [Abbott Laboratories, Abbott Park, IL]; n = 123 HeartWare HVAD [Medtronic, Minneapolis, MN]). We analyzed the rate of severe device infection requiring surgical intervention or involving sepsis and the impact of severe infection on outcomes in patients on long-term LVAD support. Results: Infection occurred in 244 patients (HeartMate II, n = 186; HVAD, n = 58); severe infections developed in 160 patients (HeartMate II, n = 119; HVAD, n = 41). HeartMate II recipients had 344 severe infection events (0.63 events per patient-year [EPPY]), whereas HeartWare recipients had 89 severe infection events (0.42 EPPY; P = 0.047). HeartMate II recipients had a higher incidence of pump infections (P < 0.001). Severe infections did not significantly affect survival (P = 0.42). Conclusions: Although HeartMate II patients had a significantly higher incidence of pump infections requiring surgical treatment, survival was not adversely affected. The difference in postoperative infection rates may be an important factor in device type selection.

Original languageEnglish (US)
Pages (from-to)82-91
Number of pages10
JournalJournal of Cardiac Surgery
Volume34
Issue number2
DOIs
StatePublished - Feb 1 2019
Externally publishedYes

Fingerprint

Heart-Assist Devices
Equipment and Supplies
Survival
Incidence
Infection
Therapeutics
Heart Failure
Sepsis

Keywords

  • circulatory support devices
  • heart failure
  • infection
  • left ventricular assist device

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Severe LVAD-related infections requiring surgical treatment : Incidence, predictors, effect on survival, and impact of device selection. / Olmsted, Randall Z.; Critsinelis, Andre; Kurihara, Chitaru; Kawabori, Masashi; Sugiura, Tadahisa; Civitello, Andrew B.; Morgan, Jeffrey A.

In: Journal of Cardiac Surgery, Vol. 34, No. 2, 01.02.2019, p. 82-91.

Research output: Contribution to journalArticle

Olmsted, Randall Z. ; Critsinelis, Andre ; Kurihara, Chitaru ; Kawabori, Masashi ; Sugiura, Tadahisa ; Civitello, Andrew B. ; Morgan, Jeffrey A. / Severe LVAD-related infections requiring surgical treatment : Incidence, predictors, effect on survival, and impact of device selection. In: Journal of Cardiac Surgery. 2019 ; Vol. 34, No. 2. pp. 82-91.
@article{7c9c578ba9f344ae8dca27e7520f4dc1,
title = "Severe LVAD-related infections requiring surgical treatment: Incidence, predictors, effect on survival, and impact of device selection",
abstract = "Background: Left ventricular assist devices (LVADs) are being used more frequently for treating refractory, advanced heart failure. However, infection remains a frequent complication. In this study, we analyzed the incidence of severe infections in LVAD recipients to determine its impact on survival. Methods: From May 2009 through March 2016, 437 patients with advanced heart failure underwent implantation of a continuous-flow LVAD (n = 314, HeartMate II LVAD [Abbott Laboratories, Abbott Park, IL]; n = 123 HeartWare HVAD [Medtronic, Minneapolis, MN]). We analyzed the rate of severe device infection requiring surgical intervention or involving sepsis and the impact of severe infection on outcomes in patients on long-term LVAD support. Results: Infection occurred in 244 patients (HeartMate II, n = 186; HVAD, n = 58); severe infections developed in 160 patients (HeartMate II, n = 119; HVAD, n = 41). HeartMate II recipients had 344 severe infection events (0.63 events per patient-year [EPPY]), whereas HeartWare recipients had 89 severe infection events (0.42 EPPY; P = 0.047). HeartMate II recipients had a higher incidence of pump infections (P < 0.001). Severe infections did not significantly affect survival (P = 0.42). Conclusions: Although HeartMate II patients had a significantly higher incidence of pump infections requiring surgical treatment, survival was not adversely affected. The difference in postoperative infection rates may be an important factor in device type selection.",
keywords = "circulatory support devices, heart failure, infection, left ventricular assist device",
author = "Olmsted, {Randall Z.} and Andre Critsinelis and Chitaru Kurihara and Masashi Kawabori and Tadahisa Sugiura and Civitello, {Andrew B.} and Morgan, {Jeffrey A.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1111/jocs.13987",
language = "English (US)",
volume = "34",
pages = "82--91",
journal = "Journal of Cardiac Surgery",
issn = "0886-0440",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Severe LVAD-related infections requiring surgical treatment

T2 - Incidence, predictors, effect on survival, and impact of device selection

AU - Olmsted, Randall Z.

AU - Critsinelis, Andre

AU - Kurihara, Chitaru

AU - Kawabori, Masashi

AU - Sugiura, Tadahisa

AU - Civitello, Andrew B.

AU - Morgan, Jeffrey A.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Background: Left ventricular assist devices (LVADs) are being used more frequently for treating refractory, advanced heart failure. However, infection remains a frequent complication. In this study, we analyzed the incidence of severe infections in LVAD recipients to determine its impact on survival. Methods: From May 2009 through March 2016, 437 patients with advanced heart failure underwent implantation of a continuous-flow LVAD (n = 314, HeartMate II LVAD [Abbott Laboratories, Abbott Park, IL]; n = 123 HeartWare HVAD [Medtronic, Minneapolis, MN]). We analyzed the rate of severe device infection requiring surgical intervention or involving sepsis and the impact of severe infection on outcomes in patients on long-term LVAD support. Results: Infection occurred in 244 patients (HeartMate II, n = 186; HVAD, n = 58); severe infections developed in 160 patients (HeartMate II, n = 119; HVAD, n = 41). HeartMate II recipients had 344 severe infection events (0.63 events per patient-year [EPPY]), whereas HeartWare recipients had 89 severe infection events (0.42 EPPY; P = 0.047). HeartMate II recipients had a higher incidence of pump infections (P < 0.001). Severe infections did not significantly affect survival (P = 0.42). Conclusions: Although HeartMate II patients had a significantly higher incidence of pump infections requiring surgical treatment, survival was not adversely affected. The difference in postoperative infection rates may be an important factor in device type selection.

AB - Background: Left ventricular assist devices (LVADs) are being used more frequently for treating refractory, advanced heart failure. However, infection remains a frequent complication. In this study, we analyzed the incidence of severe infections in LVAD recipients to determine its impact on survival. Methods: From May 2009 through March 2016, 437 patients with advanced heart failure underwent implantation of a continuous-flow LVAD (n = 314, HeartMate II LVAD [Abbott Laboratories, Abbott Park, IL]; n = 123 HeartWare HVAD [Medtronic, Minneapolis, MN]). We analyzed the rate of severe device infection requiring surgical intervention or involving sepsis and the impact of severe infection on outcomes in patients on long-term LVAD support. Results: Infection occurred in 244 patients (HeartMate II, n = 186; HVAD, n = 58); severe infections developed in 160 patients (HeartMate II, n = 119; HVAD, n = 41). HeartMate II recipients had 344 severe infection events (0.63 events per patient-year [EPPY]), whereas HeartWare recipients had 89 severe infection events (0.42 EPPY; P = 0.047). HeartMate II recipients had a higher incidence of pump infections (P < 0.001). Severe infections did not significantly affect survival (P = 0.42). Conclusions: Although HeartMate II patients had a significantly higher incidence of pump infections requiring surgical treatment, survival was not adversely affected. The difference in postoperative infection rates may be an important factor in device type selection.

KW - circulatory support devices

KW - heart failure

KW - infection

KW - left ventricular assist device

UR - http://www.scopus.com/inward/record.url?scp=85060920513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060920513&partnerID=8YFLogxK

U2 - 10.1111/jocs.13987

DO - 10.1111/jocs.13987

M3 - Article

C2 - 30710496

AN - SCOPUS:85060920513

VL - 34

SP - 82

EP - 91

JO - Journal of Cardiac Surgery

JF - Journal of Cardiac Surgery

SN - 0886-0440

IS - 2

ER -